Publication | Closed Access

Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia

Hematological MalignancyOncologyPsc 833MedicineMixed-phenotype Acute LeukemiaPathologyPharmacotherapyAnti-cancer AgentPharmacologyCancer ResearchMyeloid Neoplasia